PRAX

Praxis Precision Medicines

PRAX

Attention (50-day avg)0%

Attention rank (50-day avg)#1,221

Bullish sentiment (50-day avg)77%

Price to earnings ratio-21.2

Market capitalization8B

Earnings per share-13

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-303.3M

Social

What share of all stock conversation is about PRAX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% +0

Jun 2

Praxis Precision Medicines' ($PRAX) POWER1 trial for vormatrigine in focal onset seizures missed its primary endpoint, but met the secondary 50% response rate.
The trial's primary measure (monthly seizure frequency change) was not met, but higher doses (30mg) showed more seizure reduction in the second half.
Analysts have updated price targets for $PRAX, with H.C. Wainwright lowering its target to $1201 and BTIG lowering its target to $810, both reiterated at Buy.

Generated by AI

Sentiment

Of the messages about PRAX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	64.71% +24.71	57.76% -39.54	78.99% -0.4
Bearish	—	35.29% -24.71	42.24% +39.54	21.01% +0.4

Bullish· Dec 29

$PRAX is expected to see significant growth in 2026, with a potential market size of over $2.5 billion in essential tremor.
BTIG has raised its price target for $PRAX to $843, citing strong prospects for its essential tremor drug Ulixacaltamide and major growth potential ahead of 2026.
Praxis Precision Medicines, the company behind $PRAX, has a strong 2026 catalyst path with multiple drugs in development, including Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen.

Bearish· Nov 20

Praxis Precision Medicines' ($PRAX) ulixa drug has an ineffective treatment profile with tolerability issues, with analysts expecting substantial downside ahead of its pre-NDA meeting.
The FDA is likely to re-run analysis on ulixa more conservatively, given its AE profile, which could lead to a failed Day 84 endpoint and ultimately a failed NDA.
Praxis Precision Medicines' ($PRAX) handling of dropouts in its clinical trials has been called out as "make-believe" and "absurd" by experts, with the FDA itself stating that sponsors should be harsher in their tipping point analysis in cases with high dropout rates.

Generated by AI

Topics

Of the messages about PRAX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	21.43%	55.65%	45.97%
Analysts	0%	53.57%	31.3%	31.03%
Technical Analysis	100%	1.79%	1.74%	6.01%
Macro	0%	23.21%	11.3%	16.07%
Controversies	0%	0%	0%	0.28%
Earnings	0%	0%	0%	0.64%

Announcements· Dec 29

Praxis Precision Medicines (PRAX) received Breakthrough Therapy Designation from the FDA for ulixacaltamide to treat patients with Essential Tremor disorder.
The designation is based on topline data from the Essential3 Phase 3 program, and the company expects to file a New Drug Application in early 2026, followed by FDA approval by the end of the year.
Jefferies and BTIG have reiterated their Buy ratings and raised their price targets for PRAX, citing the company's strong 2026 catalyst path and the potential for rapid uptake of ulixacaltamide in the Essential Tremor market.

Technical Analysis· Oct 16

$PRAX is showing high relative strength and has the potential to break the $200 level, with some analysts predicting a target range of $10-$20.
The 5-minute chart for $PRAX is displaying a potential reversal, with the EMA 9 line about to cross down the EMA 21 line, and a target price around $140.
$PRAX has broken the $200 level and hit a fresh high of $206, with some analysts expecting a gap fill to the upside, and others warning of a potential sell-off due to profit taking.

Generated by AI

Community

Of the messages about PRAX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	97.56%	71.56%	79.45%	50.83%
Newcomers	2.44%	28.44%	20.55%	49.17%

Regulars· Dec 29

BTIG raised its price target on Praxis Precision Medicines (PRAX) to $843 from $507, citing a "uniquely advantaged" launch setup for the company's essential tremor drug Ulixacaltamide.
Praxis Precision Medicines has been granted Breakthrough Therapy Designation by the FDA for Ulixacaltamide HCl in Essential Tremor, based on positive topline results from the Essential3 Phase 3 program.
BTIG named Praxis Precision Medicines a Top Pick for 2026, reiterating its Buy rating and increasing the price target to $843, which implies over 213% upside for the stock.

Newcomers· Mar 11

Newcomers to the Praxis Precision Medicines, Inc. ($PRAX) conversation are noting its decline of 4% without apparent reason.
The connection between Praxis Precision Medicines, Inc. ($PRAX) and wildfire prevention industries is a key point of discussion, with many messages highlighting the scale of vegetation management programs.
Research highlighting the economic impact of wildfires on wage losses and environmental damage is being discussed in the context of Praxis Precision Medicines, Inc. ($PRAX) and its sector, CITR.

Generated by AI

BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on September 1, 2026, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 11,535 shares of its common stock to sixty-six new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan

26d agoYahoo Finance

S&P 500 Futures Drop in Premarket Trading; Praxis Precision Meds, Science Applications Lead

29d agoBarron's

Analysts Are Bullish on Top Healthcare Stocks: Unicycive Therapeutics (UNCY), Praxis Precision Medicines (PRAX)

Detailed price information for Tempus AI Cl A (TEM-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Praxis Precision Medicines stock hits 52-week high at 388.27 USD

1mo agoInvesting.com

Also Discussed

Investors talking about PRAX also mention

#	Name	Attention
1	Pharvaris N.V. Ordinary SharesPHVS	0%0
2	INZY - Inozyme Pharma, Inc.	——
3	Olema Pharmaceuticals, Inc.OLMA	0%new
4	PRF Technologies Ltd.PRFX	0%+0
5	Alto Neuroscience Inc.ANRO	0%new
6	Spyre Therapeutics, Inc.SYRE	0%new
7	Janux Therapeutics, Inc.JANX	0%0
8	Edgewise Therapeutics Inc.EWTX	0%new
9	Nuvalent, Inc.NUVL	0%0
10	Nurix Therapeutics, Inc.NRIX	0%new

Praxis Precision Medicines, Inc.

Healthcare
Biotechnology

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing precision therapies for central nervous system disorders characterized by neuronal excitability and excitation-inhibition imbalance. Praxis Precision Medicines, Inc. applies genetic and translational neuroscience insights to create treatments for movement disorders, epilepsy, and selected psychiatric and neurological conditions. Its portfolio includes both small-molecule programs and antisense oligonucleotide therapies, supported by proprietary research platforms designed to match drug candidates to specific biological targets and patient subgroups. The company’s work centers on disorders where shared neural circuitry and genetic mechanisms may help guide more targeted therapeutic development. Praxis Precision Medicines, Inc. operates as a research-driven biotech organization with a pipeline that spans multiple CNS indications and reflects a precision medicine approach to brain health.

Website

Location

99 High Street

Boston, MA, 02110

United States

Social

What share of all stock conversation is about PRAX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% +0

Jun 2

Praxis Precision Medicines' ($PRAX) POWER1 trial for vormatrigine in focal onset seizures missed its primary endpoint, but met the secondary 50% response rate.
The trial's primary measure (monthly seizure frequency change) was not met, but higher doses (30mg) showed more seizure reduction in the second half.
Analysts have updated price targets for $PRAX, with H.C. Wainwright lowering its target to $1201 and BTIG lowering its target to $810, both reiterated at Buy.

Generated by AI

Sentiment

Of the messages about PRAX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	64.71% +24.71	57.76% -39.54	78.99% -0.4
Bearish	—	35.29% -24.71	42.24% +39.54	21.01% +0.4

Bullish· Dec 29

$PRAX is expected to see significant growth in 2026, with a potential market size of over $2.5 billion in essential tremor.
BTIG has raised its price target for $PRAX to $843, citing strong prospects for its essential tremor drug Ulixacaltamide and major growth potential ahead of 2026.
Praxis Precision Medicines, the company behind $PRAX, has a strong 2026 catalyst path with multiple drugs in development, including Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen.

Bearish· Nov 20

Praxis Precision Medicines' ($PRAX) ulixa drug has an ineffective treatment profile with tolerability issues, with analysts expecting substantial downside ahead of its pre-NDA meeting.
The FDA is likely to re-run analysis on ulixa more conservatively, given its AE profile, which could lead to a failed Day 84 endpoint and ultimately a failed NDA.
Praxis Precision Medicines' ($PRAX) handling of dropouts in its clinical trials has been called out as "make-believe" and "absurd" by experts, with the FDA itself stating that sponsors should be harsher in their tipping point analysis in cases with high dropout rates.

Generated by AI

Topics

Of the messages about PRAX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	21.43%	55.65%	45.97%
Analysts	0%	53.57%	31.3%	31.03%
Technical Analysis	100%	1.79%	1.74%	6.01%
Macro	0%	23.21%	11.3%	16.07%
Controversies	0%	0%	0%	0.28%
Earnings	0%	0%	0%	0.64%

Announcements· Dec 29

Praxis Precision Medicines (PRAX) received Breakthrough Therapy Designation from the FDA for ulixacaltamide to treat patients with Essential Tremor disorder.
The designation is based on topline data from the Essential3 Phase 3 program, and the company expects to file a New Drug Application in early 2026, followed by FDA approval by the end of the year.
Jefferies and BTIG have reiterated their Buy ratings and raised their price targets for PRAX, citing the company's strong 2026 catalyst path and the potential for rapid uptake of ulixacaltamide in the Essential Tremor market.

Technical Analysis· Oct 16

$PRAX is showing high relative strength and has the potential to break the $200 level, with some analysts predicting a target range of $10-$20.
The 5-minute chart for $PRAX is displaying a potential reversal, with the EMA 9 line about to cross down the EMA 21 line, and a target price around $140.
$PRAX has broken the $200 level and hit a fresh high of $206, with some analysts expecting a gap fill to the upside, and others warning of a potential sell-off due to profit taking.

Generated by AI

Community

Of the messages about PRAX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	97.56%	71.56%	79.45%	50.83%
Newcomers	2.44%	28.44%	20.55%	49.17%

Regulars· Dec 29

BTIG raised its price target on Praxis Precision Medicines (PRAX) to $843 from $507, citing a "uniquely advantaged" launch setup for the company's essential tremor drug Ulixacaltamide.
Praxis Precision Medicines has been granted Breakthrough Therapy Designation by the FDA for Ulixacaltamide HCl in Essential Tremor, based on positive topline results from the Essential3 Phase 3 program.
BTIG named Praxis Precision Medicines a Top Pick for 2026, reiterating its Buy rating and increasing the price target to $843, which implies over 213% upside for the stock.

Newcomers· Mar 11

Newcomers to the Praxis Precision Medicines, Inc. ($PRAX) conversation are noting its decline of 4% without apparent reason.
The connection between Praxis Precision Medicines, Inc. ($PRAX) and wildfire prevention industries is a key point of discussion, with many messages highlighting the scale of vegetation management programs.
Research highlighting the economic impact of wildfires on wage losses and environmental damage is being discussed in the context of Praxis Precision Medicines, Inc. ($PRAX) and its sector, CITR.

Generated by AI

Praxis Precision Medicines

Social

Jun 2

Bullish· Dec 29

Bearish· Nov 20

Announcements· Dec 29

Technical Analysis· Oct 16

Regulars· Dec 29

Newcomers· Mar 11

H.C. Wainwright reiterates Praxis Precision stock rating on pipeline potential

Praxis Precision Medicines: Still Potential Upside After Huge Rally (NASDAQ:PRAX)

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

S&P 500 Futures Drop in Premarket Trading; Praxis Precision Meds, Science Applications Lead

Analysts Are Bullish on Top Healthcare Stocks: Unicycive Therapeutics (UNCY), Praxis Precision Medicines (PRAX)

Praxis Precision Medicines stock hits 52-week high at 388.27 USD

Also Discussed

Praxis Precision Medicines, Inc.

Company Information

Location

H.C. Wainwright reiterates Praxis Precision stock rating on pipeline potential

Praxis Precision Medicines: Still Potential Upside After Huge Rally (NASDAQ:PRAX)

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

S&P 500 Futures Drop in Premarket Trading; Praxis Precision Meds, Science Applications Lead

Analysts Are Bullish on Top Healthcare Stocks: Unicycive Therapeutics (UNCY), Praxis Precision Medicines (PRAX)

Praxis Precision Medicines stock hits 52-week high at 388.27 USD

Also Discussed

Social

Jun 2

Bullish· Dec 29

Bearish· Nov 20

Announcements· Dec 29

Technical Analysis· Oct 16

Regulars· Dec 29

Newcomers· Mar 11